Research programme: anti-infectives - Micrologix/UCLA
Latest Information Update: 24 Oct 2021
At a glance
- Originator Harbor-UCLA Research and Education Institute; MIGENIX
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Mycoses
Most Recent Events
- 16 Jun 2000 Preclinical development for Bacterial infections in Canada (Unknown route)
- 16 Jun 2000 Preclinical development for Mycoses in Canada (Unknown route)